HIV

FDA approves expanded indication for the treatment of HIV-1 in virologically suppressed adolescents 12 years of age or older, who weigh at least 35 kg, and who are on a stable antiretroviral regimen, with no history of treatment failure or known or suspected resistance to either cabotegravir or rilpivirine.

Ibalizumab-uiyk (Trogarzo) is a CD4-directed post-attachment HIV-1 inhibitor.

FDA approves label update for Cabenuva that makes the therapy’s oral lead-in with cabotegravir and rilpivirine tablets optional.

The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.

Moderna is currently evaluating 2 HIV vaccine strategies that involve germline targeting and immune-focusing approaches.

Enhanced tools in the field of structural biology may reveal new insights into HIV that could lead to a vaccine to protect against the virus progessing to AIDS.

New strategies are needed to increase HIV prevention and testing efforts among high-risk communities.

PrEP involves taking emtricitabine/tenofovir (Truvada or Descovy) to prevent high-risk individuals from contracting HIV.

The results of a new study indicate that early initiation of treatment with combined antiretroviral therapy (cART) leads to better outcomes in patients coinfected with HIV and tuberculosis (TB).

Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.

Through the 240 weeks, numerically small median changes in eGFR and stable TC:HDL ratios were observed in both studies.

The use of a unique trimer to produce tier-2 neutralizing antibodies may help fight HIV.

Effective pre-exposure prophylaxis limits the additional price that payers should be willing to pay for the pre-exposure prophylaxis, investigators say.

Although COVID-19 vaccination rates have increased since the survey was initially conducted, the researchers noted that their results are important when considering the possibility of an annual COVID-19 vaccine.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

The analysis of 204 countries and territories reveals that AMR is now a leading cause of death worldwide, which is higher than HIV/AIDS or malaria.

These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.

Fostemsavir (Rukobia) is indicated in combination with other antiretroviral medications in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

Cabotegravir (Apretude) is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.

When left untreated, this gut condition an inflamed can accelerate arterial disease, which can lead to a heart attack or stroke, according to research from UCLA.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

The findings showed that people with HIV were 68% more likely to develop heart failure than people who did not have HIV.

Cabenuva (Cabotegravir-rilpivirine) is a 2-drug co-packaged product indicated as a complete regimen for the treatment of HIV-1 infection in adults.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.

In this video, Dr. Sherman recommends strategies for solving drug therapy related problems common to long-acting antiretroviral agents, such as missed doses, adverse drug reactions and drug–drug interactions.

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.

In this video, Dr. Sherman describes the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long acting injectable antiretroviral therapy agents.

In this video, Dr. Sherman describes what pre-exposure prophylaxis is and how long-acting injectable antiretroviral agents can help to prevent HIV and may even improve adherence.

Marinol is a cannabinoid indicated for anorexia associated with weight loss in patients with AIDS.